Under construction – not a live service
Sign in
Taking people in ChinaPhase 2

Imaging Test Using CD70 Targeting for Kidney Cancer and Lymphoma

Tests a CD70-targeted PET scan to help detect kidney cancer and lymphoma in adults.

Plain-language title generated from the registry record
Registry title: CD70-targeted immunoPET Imaging of Malignant Cancers

Key facts

Where
Shanghai, ChinaSee the site
Phase
Phase 2

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with renal cancer (especially clear cell), lymphoma or nasopharyngeal cancer, or with a suspected one on imaging. It tests a new CD70-targeted PET/CT scan.

Age
18 to 80 years
Sex
Men and women can join.
Disease stage
Renal cancer (especially clear cell), lymphoma or nasopharyngeal cancer, confirmed by tissue test or suspected on imaging.

Main reasons for not taking part

  • Pregnancy
  • Severe liver or kidney insufficiency
  • Allergy to single-domain antibody radiopharmaceuticals

Read by machine on 12 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Source: NCT06852638, who can take part

Where in China

  • Renji Hospital, School of Medicine, Shanghai Jiao Tong UniversityShanghai, ChinaContact: Weijun WeiTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
RenJi Hospital
Trial code
NCT06852638
Record updated
12 May 2026
Original description
This study aims to determine the value of cluster of differentiation (CD70)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging for diagnosing human malignancies, including renal cell carcinoma (particularly clear cell renal cell carcinoma), lymphoma, and nasopharyngeal carcinoma (NPC), among others.Read full original descriptionShow less

CD70-targeted PET/ CT in the Diagnosis of Malignant Cancers

This study aims to determine the value of cluster of differentiation (CD70)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging for diagnosing human malignancies, including renal cell carcinoma (particularly clear cell renal cell carcinoma), lymphoma, and nasopharyngeal carcinoma (NPC), among others.

Inclusion: Aged 18-80 year-old and of either sex；; Histologically confirmed diagnosis of renal cancer (especially ccRCC)/lymphoma/NPC or suspected renal cancer/lymphoma/NPC by diagnostic imaging; Capable of giving signed informed consent, including compliance with the requirements and restrictions in the informed consent form (ICF) and this protocol.

Exclusion: Severe hepatic and renal insufficiency; Allergic to single-domain antibody radiopharmaceuticals; Pregnancy；.

ClinicalTrials.gov NCT06852638